Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
about
Hepatitis C: a review for primary care physiciansPeginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis CAntiviral treatment for chronic hepatitis C in patients with human immunodeficiency virusAntiviral drugs for viruses other than human immunodeficiency virusInterferon-Free Treatments for Chronic Hepatitis C Genotype 1 InfectionKASL clinical practice guidelines: management of hepatitis CSimeprevir with pegylated interferon alfa 2a plus ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a meta-analysis and historical comparisonBenign and Malignant Hematological Manifestations of Chronic Hepatitis C Virus InfectionRole of liver transplantation in human immunodeficiency virus positive patientsHepatitis C: Treatment of difficult to treat patientsHepatitis C in human immunodeficiency virus co-infected individuals: Is this still a "special population"?New treatments for genotype 1 chronic hepatitis C - focus on simeprevirLiver safety assessment in special populations (hepatitis B, C, and oncology trials)Barriers to hepatitis C antiviral therapy in HIV/HCV co-infected patients in the United States: a reviewEffect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: results of a randomized clinical studyComparison of serum hepatitis C virus (HCV) RNA and core antigen levels in patients coinfected with human immunodeficiency virus and HCV and treated with interferon plus ribavirin.Impaired Hepatitis C Virus-Specific T Cell Responses and Recurrent Hepatitis C Virus in HIV CoinfectionRapid and early virological response to chronic hepatitis C treatment with IFN 2b or PEG-IFN 2b plus ribavirin in HIV/HCV co-infected patientsTherapeutic issues in HIV/HCV-coinfected patientsEarly ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirinBaseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in HIV/Hepatitis C Virus-Coinfected PatientsCoinfection with Hepatitis C Virus and Human Immunodeficiency Virus: Virological, Immunological, and Clinical OutcomesManagement of hepatitis C virus infection in HIV/HCV co-infected patients: Clinical reviewAPRI as a predictor of early viral response in chronic hepatitis C patientsHepatitis C Viral Kinetics During Treatment With Peg IFN-alpha-2b in HIV/HCV Coinfected Patients as a Function of Baseline CD4+ T-Cell CountsEffective Treatment of Injecting Drug Users With Recently Acquired Hepatitis C Virus InfectionHepatitis C Virus (HCV) Quasispecies Complexity and Selection in HCV/HIV‐Coinfected Subjects Treated with Interferon‐Based RegimensTreat Early or Wait and Monitor? A Qualitative Analysis of Provider Hepatitis C Virus Treatment Decision-Making in the Context of HIV CoinfectionRates of HCV Treatment Eligibility Among HCV-Monoinfected and HCV/HIV-Coinfected Patients in Tertiary Care Referral CentersPlasma Ribavirin Trough Concentrations at Week 4 Predict Hepatitis C Virus (HCV) Relapse in HIV-HCV-Coinfected Patients Treated for Chronic Hepatitis CHIV/Hepatitis C Virus-Coinfected Virologic Responders to Pegylated Interferon and Ribavirin Therapy More Frequently Incur Interferon-Related Adverse Events Than Nonresponders DoThe influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patientsApproved Antiviral Drugs over the Past 50 YearsRisk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysisDirect-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney diseaseHCV/HIV co-infection at a large HIV outpatient clinic in Sweden: feasibility and results of hepatitis C treatmentIP-10 predicts the first phase decline of HCV RNA and overall viral response to therapy in patients co-infected with chronic hepatitis C virus infection and HIVCost effectiveness of screening strategies for early identification of HIV and HCV infection in injection drug usersRibavirin Concentrations Do Not Predict Sustained Virological Response in HIV/HCV-Coinfected Patients Treated with Ribavirin and Pegylated Interferon in the Swiss HIV Cohort StudyGenetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin
P2860
Q22306040-CF15CEDB-C6F7-4F8E-86D4-51658E01FBEDQ24200189-1938B16B-1BF1-4355-819B-A1E4D119B129Q24240929-C27E184C-FAE0-4588-A10A-E48426A70646Q24635330-4218557E-D6A3-4EC3-B306-5D29BB8D6F0DQ26746563-2418C8BD-3901-4903-AA3E-0868FA494C82Q26752471-DCEC808C-3A0D-4026-A408-C34BB832B18AQ26769709-85DF4CE1-6947-4D1E-9F52-2E8CDB124BC6Q26775733-3111FD0D-86F0-4E06-B6AF-97C936C58E28Q26775931-68119BB5-A868-4D92-898E-178B639F40A6Q26798465-6F9B3789-E7CC-4029-85BE-902F5EF94990Q26798469-E2B7988F-DB0B-4260-B28A-CDEC3FC58424Q26853138-D48DA992-58DA-45C6-9354-A02CFCBB70A9Q27008502-66CF6AB8-025E-469E-A616-9D34BC037A99Q27010548-5F5CFEF9-F4EE-4ADC-AE8B-58A0C5C75955Q27472607-4539656F-093F-4BC8-8BEF-E5F27F41CE94Q27473034-E095D7EE-0027-4E61-94C5-F2C560977EBDQ27477797-2E50ADC5-FEFD-4200-B65A-0D17BA0D7ADCQ27481046-4AAF8881-44E9-4A23-8CF6-38F17CE452C2Q27481053-1175C8C4-C446-415A-A63C-E69D9334545BQ27481147-8ABF74E0-CEA6-426F-93CC-8981DDF7F575Q27485951-146FDA34-1673-4DA3-A92C-CD747A142F3CQ27488883-92A4395A-F349-4527-B5DC-FBCE5D09420FQ27489337-6484BE76-774D-430A-9475-CD3614F5A07EQ27490204-467FA540-EC57-4897-AA81-2B5DB445D6FFQ27490439-62FCEAB2-901A-493D-B6E4-F2BA91D99200Q27490862-F1E1B080-F736-4359-9405-7F6BF7C6EDBDQ27490972-7F8D2230-A85F-490E-B137-EA35F2E06DECQ27491016-836AA382-C321-4C54-B605-0240B05EA831Q27491310-9828FF03-8196-4060-8ED2-8518E3597D2FQ27491326-CAC2B28B-D828-421E-B872-39792D64AEB3Q27491342-9E97D314-CFFF-4E29-8ACA-34D6B742A3BFQ27491355-9EF22D25-FD20-4D4C-8DC2-7941585E6C04Q27755387-02631168-4EF6-4331-A69A-63C0EB5D9F39Q28076352-F0A8C2EF-C4AB-4201-9A7C-E64841A46018Q28077263-D23B4CEC-123D-4E74-84A3-9ABE7C998086Q28265090-99E5DBBD-76CF-425F-84C9-24C41560E58DQ28287283-9970315E-E878-4A84-95B1-BA88951D7FC3Q28483820-61DAFFA4-CDCA-4451-ADF6-86492A3083B4Q28546829-20D45C04-1B3A-403A-A4EC-469DFFBB6C2AQ28546960-534EF04F-1D63-4B92-A00F-E6FC8F43A836
P2860
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@ast
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@en
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@nl
type
label
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@ast
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@en
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@nl
prefLabel
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@ast
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@en
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@nl
P2093
P50
P921
P3181
P356
P1476
Peginterferon Alfa-2a plus rib ...... ction in HIV-infected patients
@en
P2093
Douglas T Dieterich
Eduardo Lissen
Francesca J Torriani
Frank Duff
Hoel Sette
Jean De Pamphilis
Joseph Sasadeusz
Juan Gonzalez-García
Maribel Rodriguez-Torres
Sharon Passe
P304
P3181
P356
10.1056/NEJMOA040842
P407
P577
2004-07-29T00:00:00Z